SM ENERGY SCHEDULES YEAR-END 2024 EARNINGS RELEASE AND LIVE Q&A CALL

PR Newswire


DENVER
, Feb. 4, 2025 /PRNewswire/ — SM Energy Company (the “Company”) (NYSE: SM) today announces that it plans to release its fourth quarter and full year 2024 financial and operating results and 2025 operating plan after market hours on February 19, 2025. See schedule below:

February 19, 2025 – After market close, the Company plans to issue its fourth quarter and full year 2024 financial and operating results and 2025 operating plan, which will include an earnings release, a pre-recorded webcast discussing fourth quarter and full year 2024 financial and operating results and the Company’s 2025 operating plan, and an associated presentation, all of which will be posted to the Company’s website at http://www.sm-energy.com/investors.

February 20, 2025 – Please join SM Energy management at 8:00 a.m. Mountain time/10:00 a.m. Eastern time for the 2024 financial and operating results/2025 operating plan Q&A session. This discussion will be accessible via:

ABOUT THE COMPANY

SM Energy Company is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and NGLs in the states of Texas and Utah. SM Energy routinely posts important information about the Company on its website. For more information about SM Energy, please visit its website at http://www.sm-energy.com.

SM ENERGY INVESTOR CONTACTS

Jennifer Martin Samuels, [email protected], 303-864-2507

Lindsay Miller, [email protected], 303-830-5860

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sm-energy-schedules-year-end-2024-earnings-release-and-live-qa-call-302366990.html

SOURCE SM Energy Company

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PR Newswire


SAN DIEGO
, Feb. 4, 2025 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that members of the management team will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11th at 2:40 p.m. ET.

The live event and replay of the presentation will be available under “Events and Presentations” through the investor relations section of the Company’s website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.

About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366886.html

SOURCE Regulus Therapeutics Inc.

Semler Scientific® Announces Updated BTC Activity; Monetizes Minority Investment to Purchase BTC; Purchased Additional 871 BTC; Now Holds 3,192 BTC; YTD BTC Yield of 152.2% Since July 1, 2024

PR Newswire


SANTA CLARA, Calif.
, Feb. 4, 2025 /PRNewswire/ — Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treating chronic diseases, today announced updates regarding its bitcoin (BTC) activity and holdings, and BTC Yield, a key performance indicator.

BTC Update

Between January 11, 2025 and February 3, 2025, Semler Scientific acquired 871 bitcoins for $88.5 million with proceeds generated from its January 2025 senior convertible notes offering and monetization of a portion of its minority investment in Monarch Medical Technologies, LLC. The average price of its bitcoin purchases was $101,616 per bitcoin, inclusive of fees and expenses. As of February 3, 2025, Semler Scientific held 3,192 bitcoins, which were acquired for an aggregate $280.4 million at an average purchase price of $87,854 per bitcoin, inclusive of fees and expenses.

BTC Yield as a Key Performance Indicator (KPI)

From January 1, 2025 to February 3, 2025, Semler Scientific’s BTC Yield was 21.9%. From July 1, 2024 (the first full quarter after Semler Scientific adopted its bitcoin treasury strategy) to February 3, 2025, Semler Scientific’s BTC Yield was 152.2%.

Semler Scientific uses BTC Yield as a KPI to help assess the performance of its strategy of acquiring bitcoin in a manner Semler Scientific believes is accretive to stockholders. Semler Scientific believes this KPI can be used to supplement an investor’s understanding of Semler Scientific’s decision to fund the purchase of bitcoin by issuing additional shares of its common stock or instruments convertible to common stock.

“We are thrilled with the progress we are making in growing our bitcoin stockpile,” said Eric Semler, chairman of Semler Scientific. “We were especially pleased with our successful convertible notes offering, which was substantially oversubscribed with investor demand.  Additionally, we were pleased to have monetized a part of our investment in Monarch Medical in order to buy more bitcoin.” 

BTC Yield and Basic and Assumed Diluted Shares Outstanding



           6/30/2024 



12/31/2024
 



      2/3/2025 

Total Bitcoin Holdings

877

2,298

3,192


Basic Shares Outstanding (‘000)

6,988

9,557

9,596

2030 Convertible Shares with Capped Calls $107.01

935

Options Outstanding

1,098

691

1,141


Assumed Diluted Shares Outstanding (1)

8,086

10,248

11,672


BTC Yield % (YTD 1/1/25 to 2/3/25)

21.9 %


BTC Yield % (7/1/24 to 2/3/25)

152.2 %

(1)

Assumed Diluted Shares Outstanding refers to the aggregate of Semler Scientific’s Basic Shares outstanding as of the end of each period plus all the additional shares that would result from the assumed conversion of all outstanding convertible notes and related capped calls, and exercise of all outstanding stock option awards. Assumed Diluted Shares Outstanding is not calculated using the treasury method and does not take into account any vesting conditions (in the case of equity awards), the exercise price of any stock option awards or any contractual conditions limiting convertibility of outstanding convertible notes or settlement of capped calls.

Important Information about BTC Yield KPI

BTC Yield is a KPI that represents the percentage change period-to-period of the ratio between Semler Scientific’s bitcoin holdings and its Assumed Diluted Shares Outstanding. Assumed Diluted Shares Outstanding refers to the aggregate of Semler Scientific’s actual shares of common stock outstanding as of the end of each period plus all additional shares that would result from the assumed conversion of all outstanding convertible notes and exercise of all outstanding stock option awards. Assumed Diluted Shares Outstanding is not calculated using the treasury method and does not take into account any vesting conditions (in the case of equity awards), the exercise price of any stock option awards or any contractual conditions limiting convertibility of outstanding convertible notes or settlement of capped calls.

Semler Scientific uses BTC Yield as a KPI to help assess the performance of its strategy of acquiring bitcoin in a manner Semler Scientific believes is accretive to stockholders. Semler Scientific believes this KPI can be used to supplement an investor’s understanding of its decision to fund the purchase of bitcoin by issuing additional shares of its common stock. When Semler Scientific uses this KPI, management also takes into account the various limitations of this metric, including that it assumes the outstanding convertible notes will be converted into shares of common stock and the capped calls will be settled in accordance with their respective terms.

Additionally, this KPI is not, and should not be understood as, an operating performance measure or a financial or liquidity measure. In particular, BTC Yield is not equivalent to a “yield” in the traditional financial context. It is not a measure of the return on investment Semler Scientific’s stockholders may have achieved historically or can achieve in the future by purchasing stock of Semler Scientific, or a measure of income generated by Semler Scientific’s operations or its bitcoin holdings, return on investment on its bitcoin holdings, or any other similar financial measure of the performance of its business or assets.

The trading price of Semler Scientific’s common stock is informed by numerous factors in addition to the amount of bitcoins Semler Scientific holds and number of actual or potential shares of its stock outstanding. As a result, the market value of Semler Scientific’s shares may trade at a discount or a premium relative to the market value of the bitcoin Semler Scientific holds. BTC Yield is not indicative nor predictive of the trading price of Semler Scientific’s shares of common stock. As noted above, this KPI is narrow in its purpose and is used by management to assist in assessing whether Semler Scientific is using equity capital in a manner accretive to stockholders solely as it pertains to its bitcoin holdings.

In calculating this KPI, Semler Scientific does not take into account the source of capital used for the acquisition of its bitcoin. Semler Scientific notes in particular, it has acquired bitcoin using cash flow from operations, proceeds from the sale of shares in its at-the-market (ATM) offering, as well as from the offering of convertible notes, which at the time of issuance and including the capped calls had, and may from time-to-time thereafter have, conversion prices above the current trading prices of Semler Scientific’s common stock, or as to which the holders of such convertible notes may not then be entitled to exercise the conversion rights of the notes. Conversely, if Semler Scientific’s convertible notes mature or are redeemed without being converted into common stock, Semler Scientific may be required to sell shares in quantities greater than the shares such convertible notes and related capped calls are convertible into or generate cash proceeds from the sale of bitcoin, either of which would have the effect of decreasing the BTC Yield due to changes in Semler Scientific’s bitcoin holdings and shares in ways that were not contemplated by the assumptions in calculating BTC Yield. Accordingly, this metric might overstate or understate the accretive nature of Semler Scientific’s use of capital to buy bitcoin because not all bitcoin may be acquired using proceeds of equity and convertible debt offerings and not all issuances of equity may involve the acquisition of bitcoin.

Semler Scientific’s ability to achieve positive BTC Yield may depend on a variety of factors, including its ability to generate cash from operations in excess of its fixed charges and other expenses, as well as factors outside of its control, such as the availability of debt and equity financing on favorable terms. Past performance is not indicative of future results.

Semler Scientific has historically not paid dividends on its shares of common stock, and by presenting this KPI, Semler Scientific makes no suggestion that it intends to do so in the future. Ownership of common stock does not represent an ownership interest in the bitcoin Semler Scientific holds.

Investors should rely on the financial statements and other disclosures contained in Semler Scientific’s filings with the Securities and Exchange Commission (SEC). This KPI is merely a supplement, not a substitute. It should be used only by sophisticated investors who understand its limited purpose and many limitations.

Forward-Looking Statements

This press release contains “forward-looking” statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words “believe,” “goal,” “may,” “will,” “intend,” “expect,” “anticipate,” “estimate,” “project,” “would,” “could” or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include statements regarding acquiring and holding bitcoin; its BTC yield; and other express or implied statements regarding the ATM offering, the recent convertible notes offering, capped call transactions and its healthcare business. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific’s actual results to differ materially from those discussed here, such as risks investing in bitcoin, including bitcoin‘s volatility; risk of implementing a bitcoin treasury strategy; risks of indebtedness from the recent convertible notes offering; risks of settlement with counterparties of the capped calls; along with those other risks related to its healthcare business and the risk factors detailed in Semler Scientific’s filings with the SEC. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this press release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.

No Offer or Solicitation

This press release does not and shall not constitute an offer to sell or a solicitation of an offer to buy any securities of Semler Scientific, nor shall there be any offer, solicitation or sale of such securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Semler Scientific, Inc.:

Semler Scientific, Inc. is a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treating chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and Semler Scientific is seeking a new 510(k) clearance for expanded indications. QuantaFlo is used by healthcare providers to evaluate their patient’s risk of mortality and major adverse cardiovascular events (MACE). Semler Scientific also invests in bitcoin and has adopted bitcoin as its primary treasury asset.

INVESTOR
CONTACT:

Renae Cormier

Chief Financial Officer
[email protected]

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/semler-scientific-announces-updated-btc-activity-monetizes-minority-investment-to-purchase-btc-purchased-additional-871-btc-now-holds-3-192-btc-ytd-btc-yield-of-152-2-since-july-1–2024–302367213.html

SOURCE Semler Scientific, Inc.

United to restart service to Tel Aviv, Israel

PR Newswire

Flights from New York/Newark to Tel Aviv resume March 15, with second daily flight resuming March 29


CHICAGO
, Feb. 4, 2025 /PRNewswire/ — United is pleased to announce plans to restart New York/Newark to Tel Aviv service on March 15, with a second daily flight planned to begin March 29. This resumption follows a detailed assessment of operational considerations for the region and close work with the unions who represent our flight attendants and pilots. The flights will be operated on Boeing 787-10s.

United has a longstanding commitment to serving Tel Aviv, and this return will make United the first U.S. airline to resume service this year. United also offers connections to Tel Aviv through partners including Lufthansa Group airlines. United will continue to evaluate opportunities to restore additional flights based on demand.

About United

At United, Good Leads The Way. With U.S. hubs in Chicago, Denver, Houston, Los Angeles, New York/Newark, San Francisco and Washington, D.C., United operates the most comprehensive global route network among North American carriers and is now the largest airline in the world as measured by available seat miles. For more about how to join the United team, please visit www.united.com/careers and more information about the company is at www.united.com. United Airlines Holdings, Inc., the parent company of United Airlines, Inc., is traded on the Nasdaq under the symbol “UAL”.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/united-to-restart-service-to-tel-aviv-israel-302366849.html

SOURCE United Airlines

Waters ElectroForce Apex 1 Instrument Offers Increased Versatility, Simplicity, and Speed to Mechanical Testing of Advanced Polymer Materials

PR Newswire

News Summary:

  • Offers increased versatility and data-driven insights with 43% greater motor stroke range (100 mm),1 expanding testing to more materials across diverse industries.
  • Improved dynamic performance completes fatigue testing up to 30% faster than the competition,2 increasing the speed of product development and validation.
  • Designed to simplify testing workflows, with automated controls and fewer process steps to help reduce operator errors and enable safer, more confident testing.


ANAHEIM, Calif., and MILFORD, Mass.
, Feb. 4, 2025 /PRNewswire/ – MD&M West Waters Corporation (NYSE:WAT) today announced the launch of the TA Instruments™ ElectroForce™ Apex 1 Mechanical Testing Instrument, specially designed for increased versatility, speed, and ease of use to support precise tensile and fatigue testing of high performance and lightweight polymers and composites.

ElectroForce™ Apex 1 Instrument is for precise, safe, and reliable testing to inform material selection and design.

“As an additive manufacturing company, we build 3D-printed polymer parts that are increasingly being used in highly demanding applications where strength and durability are essential. After one short training session, we were able to use the ElectroForce Apex 1 Instrument to easily conduct tensile and fatigue testing to characterize our new materials,” said Javier Ramos, Chief Technology Officer for Inkbit Corporation. “The ease of use and quick time to results have given us the confidence to explore a greater range of materials, testing the limit of our manufactured materials and processes.”

Material strength and durability testing is increasingly important for accelerating the development of products in demanding applications such as those in the medical device, polymer, aerospace, automotive, and additive manufacturing industries. The ElectroForce Apex 1 Instrument’s motor stroke range is at least 43% greater than the competition, providing laboratories and manufacturers the versatility to perform monotonic and fatigue testing across a greater variety of materials. The increased motor stroke range also speeds testing by up to 30%, which can reduce costs early in development by helping users to identify and eliminate weaknesses in material selection and design, before the validation or post-launch phase.

“As manufacturers pivot towards developing and using more high-quality sustainable materials, the need for simple, accurate, and affordable mechanical testing becomes increasingly important,” said Yu Cheng, vice president of Research and Development and Product Solutions, TA Instruments Division of Waters. “The ElectroForce Apex 1 Instrument was designed for customers looking for precise, safe, and reliable testing to inform material selection and design, as well as component and product performance assessments.”

Designed to reduce operator process steps and errors, the ElectroForce Apex 1 Instrument comes equipped with new software features, including TuneIQ™ Technology, which can automatically tune the instrument without operator intervention and without additional, invasive stress or strain applied to the sample. The new motor control system improves break-stop capabilities during mechanical testing, increasing workflow options and operator confidence to run longer experiments unsupervised, including overnight. The instrument also comes with intelligent data acquisition to help prevent computer hard drive overload by selecting test-specific data parameters and limiting collection to more critical and manageable data.

Waters ElectroForce™ Apex 1 Mechanical Testing Instrument is available for order today.

Additional Resources

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

TA Instruments, ElectroForce, and TuneIQ are trademarks of Waters Technologies Corporation.


1 Motor stroke range compared to Competitor System 1 (70mm) and Competitor System 2 (60mm).
2 Based on performance curves vs. competition, which show maximum of 23Hz vs. ElectroForce Apex 1 Instrument’s 30Hz performance during a 5 mm sinusoidal amplitude fatigue test.

Contact:

Laura Borland

Director, TA Instruments Business Communications
Waters Corporation
[email protected]
+1.302.367.6958

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-electroforce-apex-1-instrument-offers-increased-versatility-simplicity-and-speed-to-mechanical-testing-of-advanced-polymer-materials-302366790.html

SOURCE Waters Corporation

Tactile Medical Expands Launch of Nimbl™ to Include Patients with Lower Extremity Lymphedema

Next-Generation Platform Now Available for Both Upper and Lower Extremity Conditions

MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States (U.S.) for the treatment of both upper and lower extremity lymphedema. Nimbl’s expanded availability to include lower extremity conditions (“phlebolymphedema”) follows its commercial introduction in October 2024, initially focused on treating patients suffering from upper extremity lymphedema.

“On the heels of Nimbl’s launch for patients with upper extremity swelling, we are pleased to now expand access to the 16 million Americans with chronic swelling in the lower extremities,” said Sheri Dodd, Chief Executive Officer at Tactile Medical. “These patients require effective, convenient therapies to help manage their symptoms. With Nimbl, they now have access to a solution which embodies patient-focused innovation and reflects our commitment to serving patients and improving their care experience.”

Nimbl is the smallest pneumatic compression device (PCD) of its kind, featuring a compact controller that is 68% lighter and 40% smaller than the Company’s current generation PCD. The lower extremity garment uses 94% less hosing, making the device easy to transport and manage. Nimbl is the only basic PCD with Bluetooth® connectivity, providing patients a way to track their treatments and symptom progress with the Company’s free Kylee™ digital application.

“Nimbl for lower extremity lymphedema is intentionally designed as a user-friendly, patient-centric treatment option that is comfortable, clinically effective, and optimized for increased adherence,” said Tony Gasparis, MD, Chief Medical Officer at Tactile Medical. “Its physical dimensions and significant reduction in hose length afford patients the ability to more easily transport Nimbl around the home, or take it with them when traveling, providing an improved all around patient experience.”


About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries:

Sam Bentzinger
Gilmartin Group
[email protected]



Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 31,101 restricted stock units (“RSUs”) to two newly hired employees.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:

Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
[email protected]

Media Contact:

Glenn Silver
FINN Partners
[email protected]



Lifeward to Host Virtual Investor Event to Discuss Commercial Strategy, Key Initiatives, and Financial Outlook on February 20, 2025

MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it will host a virtual Investor Event on Thursday, February 20, 2025, beginning at 10:00 am EST. The event will feature presentations and question-and-answer sessions by members of the executive leadership team on the Company’s strategy, key initiatives, and financial outlook. To register for the webcast, click here.

In addition, the event will highlight innovative products from the Lifeward portfolio, including the ReWalk Exoskeleton, which addresses unmet medical needs for people with spinal cord injuries, and the AlterG Anti-Gravity System, standard of care for rehabilitation of a broad range of orthopedic and neurological conditions.

The Investor Event will be held virtually with a webcast available for investors, analysts, the media, and other interested parties who wish to join. The live webcast and subsequent replay of the event will be available on the Investor Relations section of the Lifeward website at GoLifeward.com.

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the MyoCycle FES System, and the ReStore Exo-Suit.

Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit GoLifeward.com.

Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.

Lifeward Media Relations:

Kathleen O’Donnell
VP Marketing & New Business Development
Lifeward Ltd.
E: [email protected]

Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward Ltd.
E: [email protected]



Vital Farms Launches “Good Eggs. No Shortcuts.” Campaign That Highlights Why The Best Eggs Come From Giving A Sh*t

New campaign in partnership with GUT Miami features real Vital Farms farmers committed to animal welfare

AUSTIN, Texas, Feb. 04, 2025 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today announced the launch of a new brand campaign titled “Good Eggs. No Shortcuts.” that celebrates the brand’s commitment to delivering on its purpose to improve the lives of people, animals, and the planet through food.

Developed in partnership with GUT Miami, “Good Eggs. No Shortcuts.” features documentary-style interviews with four real-life Vital Farms family farmers that capture their humorous and authentic responses that underscore their relentless hard work and dedication to animal welfare. For example, when posed with the question “Vital Farms’ farmers give their hens a lot of attention. Is it really necessary to give them that much?” farmer Jason responds simply “Nope” while giving one of the feathered girls some TLC.

“’Good Eggs. No Shortcuts.’ is a perfect illustration of Vital Farms’ commitment to being bullsh*t-free and doing right by all our stakeholders, even if it means taking the longer road when deciding how our hens should be treated,” said Heather Mace, Vital Farms Senior Director of Marketing, Campaigns & Creative. “We hear from consumers every day that we’re ‘the good eggs,’ and we wanted to show people why we’re the good eggs. This campaign celebrates the hard work that our 425+ farmers like Amanda, Jason, Matt and Tanner do every day to care for their hens.”

“The world is constantly telling us to move faster, cut corners, and optimize everything. But Vital Farms farmers know that getting good eggs comes from taking no shortcuts,” said Juan Javier Peña Plaza, Chief Creative Officer, GUT Miami. “Our goal with these spots is to show farmers’ determination to go above and beyond to keep their flocks healthy and happy. All that time, care, and commitment to keeping it bullsh*t-free makes all the difference in your eggs.”

“Good Eggs. No Shortcuts.” is rolling out across linear and streaming television and online and social platforms including Netflix, Hulu, Disney+, Reddit, Meta, Snapchat, Spotify and YouTube.

ABOUT VITAL FARMS

Vital Farms (Nasdaq: VITL) is a Certified B Corporation that offers a range of ethically produced foods nationwide. Started on a single farm in Austin, Texas in 2007, Vital Farms is now a national consumer brand that works with over 425 family farms and is the leading U.S. brand of pasture-raised eggs by retail dollar sales. Vital Farms’ ethics are exemplified by its focus on the humane treatment of farm animals and sustainable farming practices. In addition, as a Delaware public benefit corporation, Vital Farms prioritizes the long-term benefits of each of its stakeholders, including farmers and suppliers, customers and consumers, communities and the environment, and crew members and stockholders. Vital Farms’ products, including shell eggs, butter, hard-boiled eggs, and liquid whole eggs, are sold in approximately 24,000 stores nationwide. Vital Farms pasture-raised eggs can also be found on menus at hundreds of foodservice operators across the country. For more information, visit https://vitalfarms.com/.

Media:

Rob Discher
[email protected]

Investors:

Anthony Bucalo
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3b55dad8-484a-4556-8d85-27b296a77e47



Tokyo Lifestyle Co., Ltd. Announces Representative Director’s Share Purchase

Tokyo, Japan, Feb. 04, 2025 (GLOBE NEWSWIRE) — Tokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in Hong Kong, Japan, North America and the United Kingdom, today announced that Mr. Mei Kanayama, the Representative Director of the Company, has purchased from the open market 110,784 American Depositary Shares of the Company, representing 1,107,840 ordinary shares of the Company, as of January 28, 2025.

Mr. Mei Kanayama, Representative Director of Tokyo Lifestyle, commented, “This investment reflects my unwavering confidence in the long-term vision and strategy of Tokyo Lifestyle. As we continue to expand our global footprint and diversify our product offerings, my focus remains on driving sustainable growth and delivering maximum value for our shareholders.”

About Tokyo Lifestyle Co., Ltd.

Headquartered in Tokyo, Japan, Tokyo Lifestyle Co., Ltd. (formerly known as Yoshitsu Co., Ltd) is a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, and other products in Hong Kong, Japan, North America, and the United Kingdom. The Company offers various beauty products (including cosmetics, skincare, fragrance, and body care products), health products (including over-the-counter drugs, nutritional supplements, and medical supplies and devices), sundry products (including home goods), and other products (including food and alcoholic beverages). The Company currently sells its products through directly-operated physical stores, through online stores, and to franchise stores and wholesale customers. For more information, please visit the Company’s website at https://www.ystbek.co.jp/irlibrary/.


Forward-Looking Statements

Certain statements in this press release are forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

Tokyo Lifestyle Co., Ltd.
Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao
President
Phone: +1-646-932-7242
Email: [email protected]